In the latest trading session,, 72.34 million SAB Biotherapeutics Inc (NASDAQ:SABS) shares changed hands as the company’s beta touched 0.55. With the company’s most recent per share price at $4.34 changing hands around $1.77 or 68.87% at last look, the market valuation stands at $40.33M. SABS’s current price is a discount, trading about -15.44% off its 52-week high of $5.01. The share price had its 52-week low at $1.00, which suggests the last value was 76.96% up since then. When we look at SAB Biotherapeutics Inc’s average trading volume, we note the 10-day average is 65750.0 shares, with the 3-month average coming to 47.96K.
Analysts gave the SAB Biotherapeutics Inc (SABS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended SABS as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight.
SAB Biotherapeutics Inc (NASDAQ:SABS) trade information
Instantly SABS is in green as seen in intraday trades today. With action 61.33%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 48.63%, with the 5-day performance at 61.33% in the green. However, in the 30-day time frame, SAB Biotherapeutics Inc (NASDAQ:SABS) is 143.81% up. Looking at the short shares, we see there were 33813.0 shares sold at short interest cover period of 0.54 days.
The consensus price target for the stock as assigned by Wall Street analysts is 6, meaning bulls need an upside of 27.67% from its recent market value. According to analyst projections, SABS’s forecast low is 3 with 8 as the target high. To hit the forecast high, the stock’s price needs a -84.33% plunge from its current level, while the stock would need to tank 30.88% for it to hit the projected low.
The 2025 estimates are for SAB Biotherapeutics Inc earnings to increase by 44.62%, but the outlook for the next 5-year period is at 29.58% per year.
SABS Dividends
SAB Biotherapeutics Inc is expected to release its next quarterly earnings report on 2025-May-09.
SAB Biotherapeutics Inc (NASDAQ:SABS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 21.02% of SAB Biotherapeutics Inc shares while 23.99% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 30.37%. There are 23.99% institutions holding the SAB Biotherapeutics Inc stock share, with BVF INC/IL the top institutional holder. As of 2024-06-30, the company held 9.9171% of the shares, roughly 0.92 million SABS shares worth $2.85 million.
RTW INVESTMENTS, LP holds the second largest percentage of outstanding shares, with 8.2868% or 0.77 million shares worth $2.38 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund . With 232.57 shares estimated at $0.97 million under it, the former controlled 2.50% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund held about 0.47% of the shares, roughly 43.81 shares worth around $0.18 million.
